Scopus Asset Management’s Theriva Biologics TOVX Stock Holding History

Scopus Asset Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-900	Closed	-$107K	–	377
2020 Q3	$107K	Hold	900	–	–	﹤0.01%	236
2020 Q2	$115K	Hold	900	–	–	﹤0.01%	188
2020 Q1	$72K	Hold	900	–	–	0.01%	99
2019 Q4	$114K	Hold	900	–	–	﹤0.01%	140
2019 Q3	$102K	Hold	900	–	–	﹤0.01%	124
2019 Q2	$124K	Hold	900	–	–	﹤0.01%	162
2019 Q1	$153K	Hold	900	–	–	﹤0.01%	138
2018 Q4	$126K	Hold	900	–	–	0.01%	107
2018 Q3	$585K	Buy	+900	New	+$995K	0.01%	220
2018 Q2	–	Sell	-26	Closed	-$72K	–	378
2018 Q1	$72K	Sell	26 -25	-49%	-$95.1K	﹤0.01%	284
2017 Q4	$229K	Hold	51	–	–	﹤0.01%	280
2017 Q3	$420K	Hold	51	–	–	﹤0.01%	268
2017 Q2	$254K	Hold	51	–	–	﹤0.01%	243
2017 Q1	$284K	Hold	51	–	–	﹤0.01%	213
2016 Q4	$343K	Buy	+51	New	+$524K	0.01%	183

Other funds holding TOVX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Scopus Asset Management's TOVX Position: Q4 2018 in Review

Scopus Asset Management sold out of Theriva Biologics (TOVX) in Q4 2018, closing a stake of 11 shares — an estimated $2.61K sold.

Scopus Asset Management first reported a position in TOVX in Q4 2016 and held it in 8 quarters. The position peaked at $93K in Q3 2017. 23 funds tracked by Wall St. Rank hold TOVX as of Q4 2018.

Scopus Asset Management reported no remaining Theriva Biologics position as of Q4 2018 after selling out during the quarter.
Scopus Asset Management sold 11 Theriva Biologics shares in Q4 2018, an estimated $2.61K.
Scopus Asset Management first reported a position in Theriva Biologics in Q4 2016 and held it in 8 quarters.
Scopus Asset Management's Theriva Biologics position peaked at $93K in Q3 2017.
23 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2018.

Based on Scopus Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.